<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115825</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00019309</org_study_id>
    <secondary_id>NCI-2021-10801</secondary_id>
    <secondary_id>STUDY00019309</secondary_id>
    <nct_id>NCT05115825</nct_id>
  </id_info>
  <brief_title>Pain Management for Head and Neck Cancer Survivors</brief_title>
  <official_title>Survivors of Head and Neck Cancer: Optimizing Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial improves an existing pain management program and tests its effect on head&#xD;
      and neck cancer survivors. This trial aims to find a better program to improve pain-related&#xD;
      physical functioning, mood, and quality of life in a sample of individuals who have undergone&#xD;
      treatment for head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Adapt an existing telehealth pain management intervention to target improvement of&#xD;
      pain-related physical functioning, mood, substance use, and quality of life in a local sample&#xD;
      of veteran head and neck cancer (HNC) survivors.&#xD;
&#xD;
      II. Conduct a pilot of the adapted intervention to examine the feasibility (accrual,&#xD;
      adherence, attrition) and acceptability (participant satisfaction) that will form the basis&#xD;
      of a well-powered, randomized clinical trial submitted for funding to the National Institutes&#xD;
      of Health (NIH), American Cancer Society (ACS), or Veterans Affairs (VA).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8&#xD;
      weeks.&#xD;
&#xD;
      After completion of study, patients are followed up at 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-interference</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed by Brief Pain Inventory. Will be assessed as 1-4=mild pain; 5-6 moderate pain; 7-10 severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed by the Patient Health Questionnaire. Scores of 5, 10, 15, and 20 represent point scale for mild, moderate, moderately severe and severe depression, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain coping self-efficacy</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed by the Chronic Pain Self-Efficacy Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substance use</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed by the PENN Cravings Questionnaire. Total score &gt;20 were considered to meet the threshold of craving, 15-20 were considered subthreshold, and &lt;15 were considered non-cravers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and neck cancer related quality of life</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed by the University of Michigan Quality of Life Questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prescription opioid dose</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed via patient report.</description>
  </other_outcome>
  <other_outcome>
    <measure>Prescription opioid misuse</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Will be assessed using the Chronic Opioid Misuse Measure (COMM). A score of 9 or greater is suggestive of current problematic drug-related behaviors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient acceptability</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Post-intervention, patients will be asked to rate satisfaction with the program, perception of utility with pain management, using a Likert-scale. Will inquire about patients' experiences participating in the intervention, perceived burden of participation, perception of the intervention utility, ease of use of the associated technology, and suggestions for improving the intervention.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Supportive care (Mobile Pain Coping Skills Training)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Attend Mobile Pain Coping Skills Training</description>
    <arm_group_label>Supportive care (Mobile Pain Coping Skills Training)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (Mobile Pain Coping Skills Training)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (Mobile Pain Coping Skills Training)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically confirmed diagnosis of HNC for which they have completed curative cancer&#xD;
             treatment at the VA hospital or Oregon Health &amp; Science University (OHSU) within the&#xD;
             6-24 months following treatment&#xD;
&#xD;
          -  Self-reported current pain of 4 or higher, using the 0-10 Numeric Pain Rating (NRS)&#xD;
             (0=&quot;no pain&quot; to 10=&quot;the worst pain imaginable&quot;)&#xD;
&#xD;
          -  Self-report of pain 4 or higher on two occasions, more than three weeks apart, since&#xD;
             the completion of curative treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolled in hospice&#xD;
&#xD;
          -  Have substantial hearing or visual difficulties that would impair ability to&#xD;
             participate&#xD;
&#xD;
          -  Have inadequate cognitive functioning as indicated by medical record review and/or&#xD;
             interactions with clinical staff. If needed we can follow up with the St. Louis&#xD;
             University Mental State Examination (score of &lt; 22/30) (SLUMS); or&#xD;
&#xD;
          -  Have untreated severe psychiatric illness that would impact the ability to consent and&#xD;
             participate in the intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon M Nugent, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Winchell</last_name>
      <phone>503-220-8262</phone>
      <email>kara.winchell@va.gov</email>
    </contact>
    <investigator>
      <last_name>Shannon M. Nugent, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Winchell</last_name>
      <phone>503-220-8262</phone>
      <email>kara.winchell@va.gov</email>
    </contact>
    <investigator>
      <last_name>Shannon M. Nugent, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Shannon Nugent, Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

